Braveheart Bio, Inc.

US$18.60As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:BRVEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE —
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap US$1.518B
ROIC —
SE Grade™
Value
Quality
Moat
Consensus
Reference
$20
9.13%
(59.48%)
Buy 10|3|3|9|0
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.39
0.39
0.42
0.47
14.29%
7.76%
12.71%
31.07%
Revenue$M
124.0
127.0
131.3
132.9
4.15%
9.22%
8.30%
12.71%
Peers (US$1.518B)
Cap (US$)
PE
1.469B
—
1.522B
—
Capital
TTM
5Y
10Y
Leveragex
0.914
(0.020)
(0.019)
EBIT/Intx
0.898
0.370
0.387
Own earn%
(123.45)
7.47
23.63
Sh yield%
40.09
23.70
24.59
Owners
Insiders/Inst%
14.01
45.91
Short interest%
4.71
SBC / revenue%
3.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
13–17
$1 testx
0.1
Incr. ROIC%
9